CD274 and melanoma: For immunotherapies, it is known that ipilimumab (cytotoxic T-cell antigen-4 inhibitor) has a good curative effect on advanced melanoma [11] and PD-L1 monoclonal antibody (immune checkpoint inhibitor) is sensitive to melanoma [12], non-small cell lung cancer [13], Hodgkin’s lymphoma [14] and urothelial carcinoma [15].